Refine
Year of publication
Document Type
- Conference Proceeding (58)
- Book (7)
- Article (unreviewed) (7)
- Article (reviewed) (3)
- Part of a Book (1)
- Patent (1)
Conference Type
- Konferenz-Abstract (46)
- Konferenzartikel (10)
- Konferenz-Poster (1)
- Sonstiges (1)
Language
- English (61)
- German (15)
- Other language (1)
Has Fulltext
- no (77) (remove)
Is part of the Bibliography
- yes (77)
Keywords
- Abtragung (6)
- Herz (5)
- Defibrillator (4)
- Elektrokardiogramm (4)
- Herzkrankheit (3)
- Hochfrequenztechnik (3)
- Katheter (3)
- Medizintechnik (3)
- Synchronisierung (3)
- Blockdiagramm (2)
Institute
Open Access
- Open Access (31)
- Closed Access (27)
- Closed (4)
ECG simulators, available on the market, imitate the electric activity of the heart in a simplified manner. Thus, they are suitable for education purposes but not really for testing algorithms to recognize complex arrhythmias needed for pacemakers and implantable defibrillators. Especially certain discrimination between various morphologies of atrial and ventricular fibrillation needs simulators providing native electrograms of different patients’ heart rhythm events. This explains the necessity to develop an ECG simulator providing high-resolution native intracardiac and surface electrograms of in-vivo rhythm events. In this paper we demonstrate an approach for an ECG simulator based on a consumer multichannel soundcard and a corresponding software application for a laptop computer. This Live-ECG Simulator is able to handle invasive electrogram recordings from electrophysiological studies and send the data to a modified external soundcard for subsequent digital to analog conversion. The hardware is completed with an electronic circuit providing level adjustment to adapt the output amplitude to the input conditions of several cardiac implants.
New frontiers of supraventricular tachycardia and atrial flutter evaluation and catheter ablation
(2012)
Radiofrequency catheter ablation (RFCA) has revolutionized treatment for tachyarrhythmias and has become first-line therapy for some tachycardias. Although developed in the 1980s and widely applied in the 1990s, the technique is still in development. Transesophageal atrial pacing (TAP) can used for initiation and termination of supraventricular tachycardia (SVT).
Methods: The paroxysmal SVT include a wide spectrum of disorders including, in descending order of frequency, atrial flutter, atrioventricular (AV) nodal reentry, Wolff-Parkinson-White syndrome, and atrial tachycardia. While not life-threatening in most cases, they may cause important symptoms, such as palpitations, chest discomfort, breathlessness, anxiety, and syncope, which significantly impair quality of life. Medical therapy has variable efficacy, and most patients are not rendered free of symptoms. Research over the past several decades has revealed fundamental mechanisms involved in the initiation and maintenance of all of these arrhythmias. Knowledge of mechanisms has in turn led to highly effective surgical and catheter-based treatments. The supraventricular arrhythmias and their treatment are described in this report. SVT initiation was analysed with programmed TAP in 49 patients with palpitations (age 47 ± 17 years, 24 females, 25 males).
Results: In comparison to antiarrhythmic drug therapy the radiofrequency catheter ablation in patients suffering from atrial flutter, atrioventricular nodal reentry, atrioventricular reentry and atrial tachycardia is the better choice in most cases. TAP SVT initiation was possible in 23 patients before RFCA. Atrial cycle length of SVT was 320 ± 59 ms. We initiated AV nodal reentrant tachycardia (AVNRT, n=15), atrial tachycardia (AT, n=6) and AV reentrant tachycardia with Kent pathway conduction (AVRT, n=2) before RFCA.
Conclusions: Radiofrequency catheter ablation is a successful and safe method to cure most patients with paroxysmal supraventricular tachycardias. TAP allowed initiation and termination of SVT especially in outpatients.
Cardiac resynchronization therapy with biventricular pacing is an established therapy for heart failure patients with electrical left ventricular desynchronization. The aim of this study was to evaluate left atrial conduction delay, intra left atrial conduction delay, left ventricular conduction delay and intra left ventricular conduction delay in heart failure patients using novel signal averaging transesophageal left heart ECG software.
Methods: 8 heart failure patients with dilated cardiomyopathy (DCM), age 68 ± 9 years, New York Heart Association (NYHA) class 2.9 ± 0.2, 24.8 ± 6.7 % left ventricular ejection fraction, 188.8 ± 15.5 ms QRS duration and 8 heart failure patients with ischaemic cardiomyopathy (ICM), age 67 ± 8 years, NYHA class 2.9 ± 0.3, 32.5 ± 7.4 % left ventricular ejection fraction and 167.6 ± 19.4 ms QRS duration were analysed with transesophageal and transthoracic ECG by Bard LabDuo EP system and novel National Intruments LabView signal averaging ECG software.
Results: The electrical left atrial conduction delay was 71.3 ± 17.6 ms in ICM versus 72.3 ± 12.4 ms in DCM, intra left atrial conduction delay 66.8 ± 8.6 ms in ICM versus 63.4 ± 10.9 ms in DCM and left cardiac AV delay 180.5 ± 32.6 ms in ICM versus 152.4 ± 30.4 ms in DCM. The electrical left ventricular conduction delay was 40.9 ± 7.5 ms in ICM versus 42.6 ± 17 ms in DCM and intra left ventricular conduction delay 105.6 ± 19.3 ms in ICM versus 128.3 ± 24.1 ms in DCM.
Conclusions: Left heart signal averaging ECG can be utilized to analyse left atrial conduction delay, intra left atrial conduction delay, left ventricular conduction delay and intra left ventricular conduction delay to improve patient selection for cardiac resynchronization therapy.
Non-responder rate in cardiac resynchronization therapy (CRT) could be partly decreased by individualized parameter optimization excluding adverse hemodynamic timing. In heart failure patients with sinus rhythm, an atrial kick enables the completion of atrial contraction and may significantly enhance the ventricular filling. Compared to that, exclusion of atrial kick is a sign of suboptimal atrioventricular timing. However, the recognition of atrial kick by echocardiography will be negatively affected in patients requiring a very short or long AV delays.
In-vivo and in-vitro comparison of implant-based CRT optimization - What provide new algorithms?
(2011)
Introduction: In cardiac resynchronization therapy (CRT), individual AV delay (AVD) optimization can effectively increase hemodynamics and reduce non-responder rate. Accurate, automatic and easily comprehensible algorithms for the follow-up are desirable. QuickOpt is the first attempt of a semi-automatic intracardiac electrogram (IEGM) based AVD algorithm. We aimed to compare its accuracy and usefulness by in-vitro and in-vivo studies.
Methods: Using the programmable ARSI-4 four-chamber heart rhythm and IEGM simulator (HKP, Germany), the QuickOpt feature of an Epic HF system (St. Jude, USA) was tested in-vitro by simulated atrial IEGM amplitudes between 0.3 and 3.5mV during both, manual and automatic atrial sensing between 0.2 and 1.0mV. Subsequently, in 21 heart failure patients with implanted biventricular defibrillators, QuickOpt was performed in-vivo. Results of the algorithm for VDD and DDD stimulation were compared with echo AV delay optimization.
Results: In-vitro simulations demonstrated a QuickOpt measuring accuracy of ± 8ms. Depending on atrial IEGM amplitude, the algorithm proposed optimal AVD between 90 and 150ms for VDD and between 140 and 200ms for DDD operation, respectively. In-vivo, QuickOpt difference between individual AVD in DDD and VDD mode was either 50ms (20pts) or 40ms (1pt). QuickOpt and echo AVD differed by 41 ± 25ms (7 – 90ms) in VDD and by 18 ± 24ms (17-50ms) in DDD operation. Individual echo AVD difference between both modes was 73 ± 20ms (30-100ms).
Conclusion: The study demonstrates the value of in-vitro studies. It predicted QuickOpt deficiencies regarding IEGM amplitude dependent AVD proposals constrained to fixed individual differences between DDD and VDD mode. Consequently, in-vivo, the algorithm provided AVD of predominantly longer duration than echo in both modes. Accepting echo individualization as gold standard, QuickOpt should not be used alone to optimize AVD in CRT patients.